嵌合抗原受体
癌症研究
抗原
生物
免疫学
T细胞
细胞生物学
免疫系统
作者
Jinsheng Han,Fei Gao,Songsong Geng,Xueshuai Ye,Tie Wang,Pingping Du,Ziqi Cai,Zexian Fu,Zhilong Zhao,Long Shi,Qingxia Li,Jianhui Cai
标识
DOI:10.1158/1535-7163.mct-19-0204
摘要
Viral-based chimeric antigen receptor-engineered T (CAR T)-cell manufacturing has potential safety risks and relatively high costs. The nonviral minicircle DNA (mcDNA) is safer for patients, cheaper to produce, and may be a more suitable technique to generate CAR T cells. In this study, we produced mcDNA-based CAR T cells specifically targeting prostate stem cell antigen (PSCA; mcDNA-PSCA-CAR T cells). Our results showed that mcDNA-PSCA-CAR T cells persisted in mouse peripheral blood as long as 28 days and demonstrated more CAR T-cell infiltration, higher cytokine secretion levels, and better antitumor effects. Together, our results suggest that mcDNA-CAR can be a safe and cost-effective platform to produce CAR T cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI